|
Age at death (year), mean (SD)
|
80.65 (6.94)
|
81.00 (7.09)
|
0.717
|
81.00 (6.63)
|
81.13 (6.40)
|
0.967
|
|
Sex, male n (%)
|
37 (61.7)
|
39 (58.2)
|
0.692
|
36 (63.2)
|
35 (58.3)
|
0.593
|
|
PMI (hour), Mean (SD)
|
3.24 (2.02)
|
3.06 (1.60)
|
0.837
|
3.25 (2.05)
|
3.15 (1.69)
|
0.846
|
|
Estimated NeuN+ (%) Mean (SD)
|
30.3 (13.1)
|
29.6 (11.3)
|
0.504
|
24.5 (12.3)
|
28.1 (9.9)
|
0.159
|
|
Estimated NeuN− (%), Mean (SD)
|
68.6 (14.1)
|
69.3 (12.7)
|
0.570
|
69.0 (15.4)
|
64.1 (12.0)
|
0.095
|
|
NIA-Reagan criteria [72], n
|
|
Criteria not met
|
59
| | |
56
| | |
|
Not AD
|
1
| | |
1
| | |
|
Low
| |
2
| | |
2
| |
|
Intermediate
| |
16
| | |
17
| |
|
High
| |
49
| | |
41
| |
|
Semiquantitative measure of neuritic plaques CERAD score [73], n
|
|
Criteria not met
|
6
| | |
6
| | |
|
Not AD
|
33
| | |
31
| | |
|
Possible AD
|
21
| | |
20
| | |
|
Probable AD
| |
8
| | |
8
| |
|
Definite AD
| |
59
| | |
52
| |
|
Braak stage, n
|
|
I
|
15
| | |
12
| | |
|
II
|
14
|
2
| |
14
|
2
| |
|
III
|
20
|
4
| |
21
|
4
| |
|
IV
|
11
|
12
| |
10
|
13
| |
|
V
| |
28
| | |
21
| |
|
VI
| |
21
| | |
20
| |
|
APOE genotype, n*
|
|
ε2/ε2
|
1
|
0
| |
2
|
0
| |
|
ε2/ε3
|
10
|
3
| |
10
|
1
| |
|
ε3/ε3
|
32
|
26
| |
30
|
26
| |
|
ε3/ε4
|
16
|
33
| |
15
|
27
| |
|
ε2/ε4
|
0
|
1
| |
0
|
1
| |
|
ε4/ε4
|
1
|
3
| |
0
|
4
| |
